Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

NSCLC Harboring NRG1 Fusion 1

Interventions

pembrolizumab 112Carboplatin 47Nivolumab 41Paclitaxel 34Cyclophosphamide 32Cisplatin 32Gemcitabine 30atezolizumab 28venetoclax 25Specimen Handling 24Pemetrexed 24Magnetic Resonance Spectroscopy 24fludarabine 22Docetaxel 22Biopsy 22Bevacizumab 22Azacitidine 22Radiotherapy 21Ipilimumab 21Radiosurgery 18Fluorouracil 18durvalumab 17Dexamethasone 17Cetuximab 17fludarabine phosphate 14Trastuzumab 14Leucovorin 14Radiation 13Injections 13Cytarabine 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × zenocutuzumab × 1 year × Clear all
NCT05588609 2026-04-27

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Partner Therapeutics, Inc.

Phase 2 Terminated
13 enrolled
GenitourinaryThoracic

NSCLC Harboring NRG1 Fusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡